AR045371A1 - ANTIGONISTS 4-CYCLALKYLAMINOPIRAZOL PYRIMIDINE OF NMDA / NR2B - Google Patents

ANTIGONISTS 4-CYCLALKYLAMINOPIRAZOL PYRIMIDINE OF NMDA / NR2B

Info

Publication number
AR045371A1
AR045371A1 ARP040102917A AR045371A1 AR 045371 A1 AR045371 A1 AR 045371A1 AR P040102917 A ARP040102917 A AR P040102917A AR 045371 A1 AR045371 A1 AR 045371A1
Authority
AR
Argentina
Prior art keywords
nmda
substituted
nr2b
cyclalkylaminopirazol
antigonists
Prior art date
Application number
Other languages
Spanish (es)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Priority to ARP040102917 priority Critical patent/AR045371A1/en
Publication of AR045371A1 publication Critical patent/AR045371A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos y sales farmacéuticamente aceptables de los mismos, que son eficaces como antagonistas de NMDA/NR2B, útiles para tratar afecciones neurológicas como por ejemplo el dolor, enfermedad de Parkinson, enfermedad de Alzheimer, epilepsia, depresión, ansiedad, daño isquémico cerebral, incluyendo la apoplejía y otras afecciones. Reivindicación 1: Un compuesto que tiene la fórmula (1) en la que R1 es un resto de fórmula (2), no sustituido o sustituido con un halógeno o -R2, donde R2 es alquilo C1-6, independientemente no sustituido o sustituido con uno o más halógenos; Y es alquilo C1-6, independientemente no sustituido o sustituido con uno o más halógenos; y sales farmacéuticamente aceptables del mismo y enantiómeros y diastereómeros individuales del mismo.Pharmaceutically acceptable compounds and salts thereof, which are effective as NMDA / NR2B antagonists, useful for treating neurological conditions such as pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, cerebral ischemic damage, including stroke and other conditions. Claim 1: A compound having the formula (1) wherein R1 is a moiety of formula (2), unsubstituted or substituted with a halogen or -R2, wherein R2 is C1-6 alkyl, independently unsubstituted or substituted with one or more halogens; Y is C1-6 alkyl, independently unsubstituted or substituted with one or more halogens; and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

ARP040102917 2004-08-13 2004-08-13 ANTIGONISTS 4-CYCLALKYLAMINOPIRAZOL PYRIMIDINE OF NMDA / NR2B AR045371A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ARP040102917 AR045371A1 (en) 2004-08-13 2004-08-13 ANTIGONISTS 4-CYCLALKYLAMINOPIRAZOL PYRIMIDINE OF NMDA / NR2B

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP040102917 AR045371A1 (en) 2004-08-13 2004-08-13 ANTIGONISTS 4-CYCLALKYLAMINOPIRAZOL PYRIMIDINE OF NMDA / NR2B

Publications (1)

Publication Number Publication Date
AR045371A1 true AR045371A1 (en) 2005-10-26

Family

ID=42778392

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102917 AR045371A1 (en) 2004-08-13 2004-08-13 ANTIGONISTS 4-CYCLALKYLAMINOPIRAZOL PYRIMIDINE OF NMDA / NR2B

Country Status (1)

Country Link
AR (1) AR045371A1 (en)

Similar Documents

Publication Publication Date Title
ECSP056192A (en) 3-FLUORO-PIPERIDINS AS ANTAGONISTS OF NMDA / NR2B
UY26872A1 (en) DERIVATIVES OF THE 4- PIRIDINE PHENYL
AR069849A1 (en) HETEROARILO DERIVATIVES AS AN OREXINE RECEIVER ANTAGONISTS
PE20081530A1 (en) NEW COMPOUNDS 617
AR058885A1 (en) 3,5-SUBSTITUTED PIPERIDINE COMPOUNDS
AR065587A1 (en) AMINOAMIDS AS AN OREXINE ANTAGONISTS
ECSP066858A (en) GSK-3 INHIBITORS
AR062387A2 (en) THE USE OF A COMPOUND DERIVED FROM IMIDAZO [1,2-A] PIRIDINA, AND A MEDICINAL PRODUCT CONTAINING IT
AR070234A1 (en) COMPOUNDS THAT INCLUDE A CICLOBUTOXI GROUP
RU2008111991A (en) ORGANIC COMPOUNDS
AR050435A1 (en) HYDROXYAMIDE DERIVATIVES, OBTAINING PROCESSES AND PHARMACEUTICAL COMPOSITIONS.
CR9980A (en) IMIDAZOLINS 4,4,5,5 TETRASUSTITUIDAS
AR058287A1 (en) ISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION
PE20191784A1 (en) VMAT2 INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS RELATING TO THEM
AR071925A1 (en) MALONAMIDS AS AN OREXINE ANTAGONISTS
GT200500242A (en) PROCESSES FOR THE PREPARATION OF 2- (2,6-DIOXOPIPERIDIN-3-IL) -1-SUBSTITUTED OXOISOINDOLINES
UY26086A1 (en) PROCEDURES AND INTERMEDIATES TO PREPARE ANTI-CANCER COMPOUNDS
AR052156A1 (en) FENIL-METANONAS BI- AND SUBSTITUTED TRICYCLES FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS
PE20061295A1 (en) ACETYLENE DERIVATIVES
PE20152032A1 (en) 3,4-DIHYDROISOQUINOLIN-2 (1H) -IL COMPOUNDS
CL2003002665A1 (en) COMPOUNDS DERIVED FROM CARBOXILIC ACIDS, ITS SALTS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION, AND ITS USE IN THE TREATMENT OF DISEASES WHERE AN INHIBITOR OF THE FACTOR Xa AND / OR AN INHIBITOR OF SERINA PROTEASA IS NECESSARY.
CR11620A (en) Derivatives of Imadazo- [1,2, b] -Piridazine for the Treatment of Tyrosine C-Met Tyrosine-mediated Disease
UY29197A1 (en) N-SULPHONYLAMINOBENCIL-2-PHENOXYACETAMIDE SUBSTITUTED COMPOUNDS
AR050297A1 (en) SUBSTITUTED HYDANTOINS
CO6260069A2 (en) TIAZOLOPIRIDIN-2-ILOXI-FENIL AND TIAZOLOPIRAZIN-2-ILOXI-FENIL AMINAS AS MODULATORS OF LEUCOTRENE A4 HYDROLASS

Legal Events

Date Code Title Description
FB Suspension of granting procedure